Journal
JOURNAL OF PHARMACEUTICAL INNOVATION
Volume -, Issue -, Pages -Publisher
SPRINGER
DOI: 10.1007/s12247-023-09725-6
Keywords
Ruthenium nanoparticles; Green synthesis; Apoptosis; Homalothecium sericeum
Categories
Ask authors/readers for more resources
In this study, ethanol extracts of Homalothecium sericeum moss were used as reducing agents for the synthesis of biocompatible ruthenium nanoparticles (RuNPs) by a green synthesis method. The synthesized RuNPs were characterized and tested for their efficacy on HCT116 human colon cancer cells. The results showed that HOM-RuNPs with a size of 70-80 nm at a dosage of 5.71 μg/ml were most effective, inducing cell death and reducing multidrug resistance protein expression.
BackgroundGreen synthesis is a simple, inexpensive, and highly efficient method for the preparation of nanoparticles. In this study, ethanol extracts of Homalothecium sericeum (HOM) moss were used as reducing agents for the synthesis of biocompatible ruthenium nanoparticles (RuNPs). The ruthenium-based green synthesis method has not been used in any other work in the literature. UV-visible spectrophotometer (UV-Vis), Zetasizer, FTIR, and EDX-SEM were used to characterize the RuNPs synthesized by the green synthesis method, and their efficacy on cell viability was tested on HCT116 human colon cancer cells.MethodsUV spectroscopic measurements were used to study the release of HOM-RuNPs. Apoptosis was assessed by measuring protein expression of p53, Bax, and Bcl-2 by Western blotting. The presence of apoptosis was confirmed by double staining with Hoechst dye/propidium iodide under a fluorescence microscope. HOM-RuNPs were also tested for BCRP/ABCG2 expression to check for drug resistance.ResultsHOM-RuNPs with a size of 70-80 nm were found to be most effective at a dosage of 5.71 mu g/ml and induced cell death by increasing the ratio of Bax/Bcl-2 and p53 expression. It was also shown to reduce multidrug resistance protein (ABCG2), suggesting that it may be useful against multidrug resistance.ConclusionRuthenium-based nanoparticles synthesized by a green synthesis technique may be a candidate for anticancer drugs in the pharmaceutical industry and deserve further attention for proof-of-concept studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available